Timing: development, readiness and dosing
You will be able to: Separate a development estimate, a released product and a clinical treatment schedule.
“How long does it take?” has at least three answers: time to discover and develop a product, time to make and release a particular batch, and the patient's dosing and follow-up schedule. A date for one stage is not a date for the others.
Before starting: Mechanism.
Read the timeline by stage
The chart shows dependencies, not a promised duration.
| Stage | What must be known | Why a forecast can change |
|---|---|---|
| Target nomination | Relevant target and intended setting | Sampling, expression and specificity may invalidate a candidate |
| Development | A usable binder, format and evidence plan | Affinity, normal-tissue binding, stability or activity may require redesign |
| Manufacture and release | Controlled process and product-specific quality criteria | Batch failure, contamination, potency or comparability problems |
| Clinical readiness | Protocol or access pathway, site capability and eligibility | Organ function, toxicity, disease state and available alternatives |
| Dosing | Route, dose, cadence, monitoring and stopping rules | Toxicity, response, progression and protocol requirements |
An established process differs from a new therapy
Manufacturing an established autologous CAR (chimeric antigen receptor)-T product can take weeks. Developing a new receptor and manufacturing process can take much longer and may never yield a clinically usable product. A quoted timeline from one platform cannot be assigned to every cellular or antibody therapy.
Likewise, developing a binder in parallel with a vaccine may save research time, but it does not establish that either treatment should be given. A binder stored as a research reagent is not automatically a released clinical drug with a validated shelf life.
Access time is a separate clock
For a new non-emergency individual-patient expanded-access IND, FDA's default is 30 days after receipt or earlier FDA notification. Emergency use may begin after FDA authorization before a written submission. A protocol under an existing IND has a different process. These rules are not universal three-month development estimates and do not remove manufacturer, institutional or ethics requirements.
Try it
A proposal gives “six months to manufacture” and “monthly dosing.” What is still missing?
Explain it back: Which product is being made, when development is complete, what release and clinical gates apply, route and duration of dosing, monitoring, and which events stop or delay treatment.
Explain it back
Use conditional milestones until the product, process and clinical plan are confirmed. An illustrative calendar is not a treatment schedule.
Takeaway
Use conditional milestones until the product, process and clinical plan are confirmed. An illustrative calendar is not a treatment schedule.
Current application
Treatment status belongs in the care plan, unresolved choices in questions, and provider-specific capabilities in companies. A mechanism lesson does not establish eligibility or a treatment plan.
Sources
Checked October 8, 2026.